Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析

◆英語タイトル:Enanta Pharmaceuticals Inc (ENTA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH139818FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). It also develops EDP-938, a potent N-protein inhibitor for respiratory syncytial virus; and programs to discover and develop chemical entities for the treatment of hepatitis B virus. The company also develops and markets protease inhibitor compounds for the treatment of hepatitis C virus through collaborative development and license agreement with AbbVie. Enanta is headquartered in Watertown, Massachusetts, the US

Enanta Pharmaceuticals Inc Key Recent Developments

Feb 18,2021: Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference
Feb 08,2021: Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended December 31, 2020
Feb 08,2021: Enanta Pharma FQ1 2021 Earnings Preview
Feb 02,2021: Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2020
Jan 26,2021: Enanta Pharmaceuticals announces the appointment of Brendan Luu as senior vice president, business development

This comprehensive SWOT profile of Enanta Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Enanta Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Enanta Pharmaceuticals Inc – Key Information
Enanta Pharmaceuticals Inc – Overview
Enanta Pharmaceuticals Inc – Key Employees
Enanta Pharmaceuticals Inc – Key Employee Biographies
Enanta Pharmaceuticals Inc – Key Operational Heads
Enanta Pharmaceuticals Inc – Major Products and Services
Enanta Pharmaceuticals Inc – History
Enanta Pharmaceuticals Inc – Company Statement
Enanta Pharmaceuticals Inc – Locations And Subsidiaries
Enanta Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Enanta Pharmaceuticals Inc – Business Description
Enanta Pharmaceuticals Inc – Corporate Strategy
Enanta Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Enanta Pharmaceuticals Inc – Strengths
Enanta Pharmaceuticals Inc – Weaknesses
Enanta Pharmaceuticals Inc – Opportunities
Enanta Pharmaceuticals Inc – Threats
Enanta Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Enanta Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Enanta Pharmaceuticals Inc, Key Information
Enanta Pharmaceuticals Inc, Key Ratios
Enanta Pharmaceuticals Inc, Share Data
Enanta Pharmaceuticals Inc, Major Products and Services
Enanta Pharmaceuticals Inc, History
Enanta Pharmaceuticals Inc, Key Employees
Enanta Pharmaceuticals Inc, Key Employee Biographies
Enanta Pharmaceuticals Inc, Key Operational Heads
Enanta Pharmaceuticals Inc, Other Locations
Enanta Pharmaceuticals Inc, Subsidiaries
Enanta Pharmaceuticals Inc, Key Competitors
Enanta Pharmaceuticals Inc, SWOT Analysis
Enanta Pharmaceuticals Inc, Ratios based on current share price
Enanta Pharmaceuticals Inc, Annual Ratios
Enanta Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GamaMabs Pharma SA-製薬・医療分野:企業M&A・提携分析
    Summary GamaMabs Pharma SA (GamaMabs) is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer. Its lead product candidate GM102, is an anti-AMHR2, Emabling engineered humanized mAb product targeting the receptor of anti-Mullerian hormone (A …
  • Teijin Ltd (3401):医療機器:M&Aディール及び事業提携情報
    Summary Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, poly …
  • AIT Austrian Institute of Technology GmbH-医療機器分野:企業M&A・提携分析
    Summary AIT Austrian Institute of Technology GmbH (AIT) is a research and technology institute that provides research development services in various fields. The institute offers research on health and environment, energy, mobility, digital safety and security, and innovation systems. Its health and …
  • Deciphera Pharmaceuticals LLC (DCPH)-製薬・医療分野:企業M&A・提携分析
    Summary Deciphera Pharmaceuticals LLC (Deciphera Pharmaceuticals) is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company's clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It uses pr …
  • United States Endoscopy Group Inc:企業の戦略的SWOT分析
    United States Endoscopy Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Gleiss Lutz Hootz Hirsch GmbH:企業の戦略的SWOT分析
    Gleiss Lutz Hootz Hirsch GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • DigitalGlobe Inc:企業の戦略的SWOT分析
    DigitalGlobe Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Angelini Group:企業の戦略的SWOT分析
    Angelini Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Calithera Biosciences Inc (CALA):企業の財務・戦略的SWOT分析
    Summary Calithera Biosciences Inc (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer . The company’s product pipeline includes CB-839, a glutamina …
  • Aquila Resources Ltd:企業の戦略・SWOT・財務分析
    Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Qatar General Electricity and Water Corporation:企業の戦略的SWOT分析
    Qatar General Electricity and Water Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Bloomsbury Publishing Plc (BMY):企業の財務・戦略的SWOT分析
    Bloomsbury Publishing Plc (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Calavo Growers, Inc. (CVGW):企業の財務・戦略的SWOT分析
    Calavo Growers, Inc. (CVGW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • PathoQuest SAS-医療機器分野:企業M&A・提携分析
    Summary PathoQuest SAS (PathoQuest) is a biotechnology company that offers game changing metagenomics approach to improve the breadth of pathogen detection. The company offers automated bioinformatics software that provide comprehensive pathogens database to produce microbiome reports. Its testing a …
  • Aker BioMarine AS:企業の戦略・SWOT・財務分析
    Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report Summary Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ContourGlobal plc (GLO):電力:M&Aディール及び事業提携情報
    Summary ContourGlobal plc (ContourGlobal) formerly ContourGlobal Ltd, is an energy company. It develops, acquires, owns, and operates wholesale power generation assets under long-term contracts. The company creates asset by taking them through the permitting, financing, and construction processes, a …
  • VIA Technologies Inc (2388):企業の財務・戦略的SWOT分析
    VIA Technologies Inc (2388) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MRI Interventions Inc (MRIC):企業の財務・戦略的SWOT分析
    Summary MRI Interventions Inc (MRI Interventions) is a medical equipment company that develops and commercializes platforms for performing invasive surgical procedures. The company’s products include systems used for performing invasive surgeries on brain and heart. Its products are used for treatin …
  • Konsortium Transnasional Berhad:企業の戦略・SWOT・財務情報
    Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PT. Bank Negara Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Negara Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Negara Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆